Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,340.00GBp
13 Jul 2018
Change (% chg)

4.00 (+0.09%)
Prev Close
4,336.00
Open
4,338.00
Day's High
4,376.50
Day's Low
4,338.00
Volume
1,537,763
Avg. Vol
3,622,299
52-wk High
4,420.00
52-wk Low
2,940.50

Select another date:

Tue, Jul 10 2018

Photo

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc , taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

UPDATE 2-Japan's Takeda gains US approval for $62 bln Shire buy

* Also needs approval from Takeda, Shire shareholders (Adds share movement)

Takeda gets key U.S. regulatory approval to buy Shire

TOKYO, July 10 Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .

Japan's Takeda to sell Osaka headquarters, could raise 60 billion yen: Nikkei

TOKYO Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc , the Nikkei business daily reported on Thursday.

Japan's Takeda to sell Osaka headquarters, could raise Y60 bln - Nikkei

TOKYO, July 5 Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc, the Nikkei business daily reported on Thursday.

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour

TOKYO A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc , failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor

TOKYO A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc , failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

UPDATE 2-Takeda shareholders bin proposal from anti-Shire group; only 10 pct in favour

* Result casts doubt on its ability to gather necessary support

Takeda shareholder group proposal fails to pass at AGM

TOKYO, June 28 A group of Takeda Pharmaceutical Co Ltd shareholders trying to build support to block the $62 billion acquisition of London-listed Shire Plc failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

Select another date: